gsk asthma inhalers recall

GlaxoSmithKline to recall almost 600,000 asthma inhalers

Sign-up to one of our many Group Actions today - use our quick and easy form to start your claim for compensation.

Begin Your Group Action Claim Today
Please note we are unable to proceed with claims involving BMW, Dacia, Ford, Honda, MINI, Mercedes-Benz & Mitsubishi.
The deadline for claims for EA189 engines passed in 2018, and claims settled in 2022. We are unable to take any claims on for vehicles with EA189 engines. We are able to take on claims for newer engine types that are NOT EA189 engines.
Our claims team will call you back at a time that's suitable to you.
Your privacy is extremely important to us.
Information on how we handle your data is in our Privacy Policy
solicitors regulation authority

GlaxoSmithKline to recall almost 600,000 asthma inhalers

Pharmaceutical company GlaxoSmithKline (GSK) are recalling hundreds of thousands of reportedly defective asthma inhalers.

The life-saving medical devices help asthma sufferers breathe, especially when suffering from asthma attacks, but a reported defect in the Ventolin inhalers has been found to provide insufficient doses.

The drug company, based in the U.K., supplies asthma inhalers to hospitals, pharmacies, retailers and wholesalers around the world, with defective units being found in the U.S.

The recall

GSK was made aware of numerous reports that inhalers had a bulge on the outside wrapper. This seems to indicate that the medicine inside is leaking out of the container and therefore may not be able to deliver a sufficient dose as expected.

It’s thought that a defect in the propellant causes the leak. In light of these concerns, GSK has so far issued a voluntary recall for some 593,000 inhalers thought to be affected by the problem.

The products affected by the recall are:

  • Ventolin HFA 200D Inhaler – 200 Actuations, lot 5ZP1708, expires Dec 2016
  • Ventolin HFA 200D Inhaler – 200 Actuations, lot 5ZP1951, expires Feb 2017

All of the asthma inhalers recalled were manufactured at one of the British company’s warehouses in North Carolina, in the U.S., and the recall has been approved by local regulators. The recall request provides instructions to “stop distributing and immediately quarantine only the lots listed above… [to] carry out a physical count and record this data” and return it to GSK’s Indianapolis branch using a prepaid shipping label.

Serious defect

Whilst it’s important that the defective inhalers in stock are returned to the manufacturer, suppliers need to take reasonable steps to inform users of the recall.

Users and carers of asthma sufferers need to know that there may be a defect in the medical devices and that they should send them back for a replacement or use an alternative device. Asthma sufferers who are denied use of an inhaler and denied a full dose of medicine from an inhaler can suffer from significant respiratory problems.

In extreme cases, a serious asthma attack can be fatal if not treated in time. Starved of oxygen, the cells in our body cannot usually function. When the brain cannot get enough oxygen, it can shut down vital organs in the body. Even partial reduction of the oxygen to the brain can cause fainting, loss of consciousness, comas and seizures. In the long term, those who survive oxygen starvation may see a decrease in the control of their limbs, leaning difficulties and memory loss.

Asthma sufferers rely on inhalers as a life-saving drug, so they must be made aware of any defects immediately.

The content of this post/page was considered accurate at the time of the original posting and/or at the time of any posted revision. The content of this page may, therefore, be out of date. The information contained within this page does not constitute legal advice. Any reliance you place on the information contained within this page is done so at your own risk.